www.fiercehealthcare.com Open in urlscan Pro
104.16.238.114  Public Scan

Submitted URL: http://go.pardot.com/e/710433/s-individual-small-group-plans/czcgh/475503416?h=OUOU3oXFx61JYrbYJgaCuGG0qcedZuXNBpR-Wh...
Effective URL: https://www.fiercehealthcare.com/payers/kff-35-monthly-insulin-cost-cap-could-benefit-1-4-americans-individual-small-group-plans
Submission: On March 25 via api from US — Scanned from DE

Form analysis 2 forms found in the DOM

GET /search-results

<form action="/search-results" method="get">
  <div class="container">
    <div class="row mb-4">
      <div class="col-11">
        <div class="text-left element-title xlarge">What are you searching for?</div>
      </div>
      <div class="col-1 search-dismiss align-items-center d-flex justify-content-end"><button type="button" data-dismiss="modal"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="times" role="img"
            xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512" class="svg-inline--fa fa-times fa-w-10">
            <path fill="currentColor"
              d="M207.6 256l107.72-107.72c6.23-6.23 6.23-16.34 0-22.58l-25.03-25.03c-6.23-6.23-16.34-6.23-22.58 0L160 208.4 52.28 100.68c-6.23-6.23-16.34-6.23-22.58 0L4.68 125.7c-6.23 6.23-6.23 16.34 0 22.58L112.4 256 4.68 363.72c-6.23 6.23-6.23 16.34 0 22.58l25.03 25.03c6.23 6.23 16.34 6.23 22.58 0L160 303.6l107.72 107.72c6.23 6.23 16.34 6.23 22.58 0l25.03-25.03c6.23-6.23 6.23-16.34 0-22.58L207.6 256z">
            </path>
          </svg></button></div>
    </div>
    <div class="row search-form mb-4">
      <div class="col d-flex align-items-center"><button type="submit" class="position-absolute"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"
            class="svg-inline--fa fa-search fa-w-16">
            <path fill="currentColor"
              d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
            </path>
          </svg></button> <input type="text" placeholder="Search" name="fulltext_search" class="w-100"></div>
    </div>
    <div class="row search-help-text font-weight-light text-align-left">
      <div class="col-md-10"> Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms. <br> Example: +water -Europe </div>
    </div>
  </div>
</form>

GET /search-results

<form action="/search-results" method="get" class="search-form d-flex align-items-center position-relative"><button type="submit" class="position-absolute"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search" role="img"
      xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" class="svg-inline--fa fa-search fa-w-16">
      <path fill="currentColor"
        d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
      </path>
    </svg></button> <input type="text" placeholder="Search" name="fulltext_search" class="w-100 gray-bg font-weight-medium"></form>

Text Content

 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Life Sciences Events


 * Providers
   * Hospitals
   * Practices
 * Health Tech
   * AI and Machine Learning
   * Digital Health
   * Telehealth
 * Finance
 * Payers
 * Regulatory
 * Special Reports

 * Resources
   * Webinars
   * Events
 * Subscribe

What are you searching for?


Enclose phrases in quotes. Use a + to require a term in results and - to exclude
terms.
Example: +water -Europe
Subscribe

 * Providers
   * Hospitals
   * Practices
   
 * Health Tech
   * AI and Machine Learning
   * Digital Health
   * Telehealth
   
 * Finance
 * Payers
 * Regulatory
 * Special Reports

 * Resources
   * Webinars
   * Events
   
 * Subscribe

 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Life Sciences Events



Payers


KFF: $35 MONTHLY INSULIN COST CAP COULD BENEFIT 1 IN 4 AMERICANS IN INDIVIDUAL,
SMALL GROUP PLANS

By Robert King Mar 24, 2022 08:00pm
Kaiser Family FoundationChuck SchumerAffordable Care Act (ACA)Ron Wyden

A $35-a-month cap on insulin costs could benefit 1 in 4 Americans in an
individual or small group plan, according to new findings from the Kaiser Family
Foundation. ((Getty/Samara Heisz))

A $35-a-month cap on out-of-pocket insulin costs could benefit more than 1 in 4
Americans on the individual and small group markets and 1 in 5 in large
employer-sponsored plans, a new analysis found. 



The analysis, published Thursday by the Kaiser Family Foundation, comes as
Democrats are working to renew efforts to install a $35 out-of-pocket monthly
cap on insulin costs that had been a part of the stalled Build Back Better Act.

“With a $35 per month cap on out-of-pocket insulin costs per product, savings
could be substantial in some cases for people who use insulin,” the analysis
said. 



Fierce Healthcare Whitepaper


LEVERAGING INNOVATION IS ESSENTIAL TO REALIZING VALUE-BASED CARE'S FULL
POTENTIAL TO TRANSFORM QUALITY AND PERFORMANCE.

Sponsored by Onduo

AI enables going beyond the one-size-fits-all to deliver precision care at the
right time to lower clinical risks and costs. Download our whitepaper to learn
more about leveraging innovations like Onduo to deliver more effective
value-based care.

Download the Whitepaper

Kaiser looked at 2018 enrollee data for all individual and small group
Affordable Care Act plans sold on and off the exchanges. It also looked at
claims data from that year from people who had large employer coverage using IBM
MarketScan data.

Overall, the analysis explored 110 million out of 160 million Americans with
private insurance. Kaiser added that about 1 million people among those studied
got an insulin prescription filled in 2018.

Researchers looked at how many enrollees paid more than $420 a year
out-of-pocket on insulin, which is the average of $35 a month.



It found that 26% in the individual market and another 31% in the small group
market paid more than $420 a year. The large employer market had only 19% of
people who paid more than that figure annually, as this group tends to have
lower deductibles and copayments.


RELATED

Class-action lawsuit alleges 4 drugmakers colluded to restrict insulin sales to
340B contract pharmacies

Low-income ACA Marketplace enrollees receiving significant cost-sharing
assistance were less likely to have out-of-pocket insulin costs averaging over
$35 per month.

Private and group plans are required to cover at least one of each dosage form
of insulin and one of each type of insulin, such as short-acting or
intermediate-acting types. 

The analysis comes as lawmakers are trying to resurrect the $35 cap, which has
gotten bipartisan support before. 



The cap, however, was included as part of the $1.75 trillion Build Back Better
Act that passed the House last year and remains mired in the Senate after
objections from Sen. Joe Manchin, D-West Virginia.

Sen. Raphael Warnock, D-Georgia, has been championing legislation to resurrect
the insulin cap, and Senate Majority Leader Chuck Schumer said during a press
conference Wednesday that making insulin more affordable was a “top priority.”

He added there is a bipartisan effort to package legislation installing a cap
with “additional policies to drive down the list price in a more comprehensive
way including having the uninsured protected.”

Schumer expects to bring the legislation up for a vote later this spring after
the Easter Senate recess.

It remains unclear whether Democrats will use the legislation to advance other,
more controversial policies such as giving Medicare the power to negotiate for
lower drug prices. Sen. Ron Wyden, D-Oregon, emphasized during a hearing in the
Senate Finance Committee last week that granting Medicare negotiation power was
a major priority.

FinanceRegulatoryPayersDrug Pricesinsulin

Our Newsletter






RELATED ARTICLES

Chutes & Ladders—Centene unveils its next CEO; Cityblock Health names co-founder
as permanent CEO
Mar 25, 2022 07:30am
AHA invests in venture capital firm SteelSky, which funds women's health
startups
Mar 24, 2022 06:35pm
Google adds appointment scheduling tool to search engine
Mar 24, 2022 04:30pm
Mayo Clinic launches AI startup program to help early-stage companies get
market-ready
Mar 24, 2022 04:10pm
See more articles
 * Connect
   * The Team
   * Advertise
 * Join Us
   * Newsletters
   * Resources
   * RSS Feeds
   * Editorial Advisory Council
 * Our Brands
   * Fierce Pharma
   * Fierce Biotech
   * Fierce Healthcare
 * Our Events
   * Life Sciences Events

 * ©2022 Questex LLC All rights reserved.
 * Terms of use
 * Privacy Policy


ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789-_~x
×
We Value Your Privacy
Settings
NextRoll, Inc. ("NextRoll") and our advertising partners use cookies and similar
technologies on this site and use personal data (e.g., your IP address). If you
consent, the cookies, device identifiers, or other information can be stored or
accessed on your device for the purposes described below. You can click "Allow
All" or "Decline All" or click Settings above to customize your consent.
NextRoll and our advertising partners process personal data to: ● Store and/or
access information on a device; ● Create a personalized content profile; ●
Select personalised content; ● Personalized ads, ad measurement and audience
insights; ● Product development. For some of the purposes above, our advertising
partners: ● Use precise geolocation data. Some of our partners rely on their
legitimate business interests to process personal data. View our advertising
partners if you wish to provide or deny consent for specific partners, review
the purposes each partner believes they have a legitimate interest for, and
object to such processing.
If you select Decline All, you will still be able to view content on this site
and you will still receive advertising, but the advertising will not be tailored
for you. You may change your setting whenever you see the Manage consent
preferences on this site.
Decline All
Allow All
Manage consent preferences